Clinical trial

An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ…

NCT00210652 · SK Life Science, Inc., Industry · Completed

Key facts

NCT number NCT00210652
Title An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy
Official title A Double-Blind, Placebo-Controlled, Dose-Titration Study to Determine Safety, Tolerability and Preliminary Efficacy of RWJ-333369 as Adjunctive Therapy in Subjects With Treatment-Resistant Partial Seizures (With or Without Secondary Generalization) or Primarily Generalized Tonic-Clonic Seizures
Lead sponsor SK Life Science, Inc., Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Epilepsy, Epilepsies, Partial
Intervention type Drug
Interventions RWJ 333369:
Enrollment 47
Start date Jul 1, 2004
Primary completion Mar 1, 2010
Completion Mar 1, 2010
First posted Sep 21, 2005
Last update posted Jan 24, 2013

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies